WHO 2022 Pituitary tumors

Page 1: Overview of the 2022 WHO Classification of Pituitary Tumors

Key Changes in Classification

  • The 5th Edition of the WHO Classification emphasizes clear distinctions among tumor types affecting the pituitary gland, notably separating:

    • Anterior lobe (adenohypophyseal) tumors

    • Posterior lobe (neurohypophyseal) tumors

    • Hypothalamic tumors

  • Major anterior lobe tumors include:

    • Pituitary Neuroendocrine Tumors (PitNETs): This encompasses well-differentiated adenohypophyseal tumors previously known as pituitary adenomas.

    • Pituitary blastoma

    • Craniopharyngiomas

Detailed Histological Subtyping

  • The new classification outlines histological subtypes for PitNETs based on:

    • Tumor cell lineage

    • Cell type

    • Specific characteristics

  • Immunohistochemistry: Routine use of pituitary transcription factors (PIT1, TPIT, SF1, GATA3, and ERα) is now endorsed to establish lineage.

  • The classification recognizes distinct tumor types with varying morphologic, molecular, and clinical differences, particularly the three PIT1-lineage PitNETs:

    • Mammosomatotroph tumors

    • Acidophil stem cell tumors

    • Null cell tumors: Classified as a diagnosis of exclusion with no adenohypophyseal differentiation.

Emphasis on Diagnosis and Management

  • The term metastatic PitNET replaces pituitary carcinoma to prevent confusion with poorly differentiated neuroendocrine carcinomas.

  • Importance of recognizing multiple synchronous tumors to avoid misclassification.

Page 2: Introduction to Pituitary Tumors

Anatomy and Function

  • The pituitary gland comprises several cell types: adenohypophyseal hormone-secreting neuroendocrine cells, posterior lobe pituicytes, axonal extensions of hypothalamic neurons, and stromal cells.

  • The sellar region is where tumors from these cell types arise. Recent advances have diversified the study of pituitary tumors beyond merely hormone production.

Advanced Understanding of Tumors

  • With molecular tools, clarity emerges on terminally differentiated cell lineages and more fluid cell types allowing transdifferentiation.

New Classification Approach

  • Tumors are now classified based on lineage determined by transcription factors and hormones, with emphasis on accuracy and tailored therapy.

Page 3: Classification of Pituitary Neuroendocrine Tumors

Nomenclature Change

  • From Pituitary Adenoma to Pituitary Neuroendocrine Tumor (PitNET):

    • Recognizes the neuroendocrine nature of these tumors.

    • Highlights the inconsistency of previous nomenclature linking benign tumors to the term adenoma.

    • Suggests a uniform classification system for neuroendocrine neoplasms.

New Diagnostic Categories

  • The classification focuses on the variety of cell types and subtypes within PitNETs, emphasizing cell lineages:

    • PIT1-lineage: Somatotrophs, lactotrophs (with subtypes), and others

    • TPIT-lineage: Corticotroph tumors

    • SF1-lineage: Gonadotroph tumors

Tumor Subtypes

  • Examples of PitNET subtypes include:

    • Somatotroph tumors (sparsely and densely granulated)

    • Lacotroph tumors categorized based on granulation degree

    • Crooke cell tumors, characterized by Crooke’s hyaline change.

Page 4: Characteristics of Tumor Subtypes

Key Features of Subtypes

  • Somatotroph tumors: Densely granulated variants usually show high hormonal activity; sparsely granulated variants are more aggressive due to delayed symptom presentation.

  • Lactotroph tumors: Commonly are sparsely granulated and associated with distinct hormonal profiles reflecting normal lactotroph status.

  • Corticotroph tumors: Recognized by their granulation and cytoplasmic features; Crooke cell tumors demonstrate aggressive characteristics despite hormonal feedback suppression.

Recognition of Tumor Precursor Cells

  • Acidophil stem cell tumors and immature PIT1-lineage tumors are distinguished from other forms, indicating a lack of terminal differentiation based on various histological evaluations.

Page 5: Pathological Correlates of Acromegaly

Associated Tumor Types

  • Acromegaly is primarily linked to the densely granulated somatotroph tumor, characterized by strongly acidophilic cells demonstrating common histological patterns.

  • Sparsely granulated somatotroph tumors: More aggressive pathway due to fewer granules, identifiable through immunohistochemistry.

Clinical and Biochemical Distinctions

  • Tumor classifications are supported through their clinical presentations, which may vary based on granulation type and hormone levels.

Page 6: Additional Correlates in Pituitary Tumors

Mixed Tumors

  • Mixed somatotroph-lactotroph tumors require accurate classification based on isolated cell populations, a significant issue for diagnostic clarity.

National Recommendations for Staining

  • Emphasis is placed on immunohistochemistry standards for diagnosis to influence patient management strategies, showcasing the varied expressions of hormones and transcription factors across tumor types.

Page 7: Hyperprolactinemia and Associated Tumors

Mechanisms and Effects

  • Hyperprolactinemia is often seen with any mass lesion affecting the sella, blocking dopamine and leading to varying levels of prolactin.

  • Prolactin-secreting tumors manifest as predominantly lactotroph tumors.

Differentiation of Tumor Types

  • Tumors classified as prolactinomas display distinct histological patterns, with malignant behaviors noted in sparsely granulated types.

Page 8: TSH Excess Pathology

Classifications of TSH-secreting Tumors

  • TSH-secreting tumors include thyrotroph tumors and various PIT1-lineage tumors, indicating diverse hormone production roles.

  • Misdiagnosing conditions such as thyrotroph hyperplasia versus pituitary neoplasms highlights the need for precision in immunohistochemical diagnostics.

Page 9: Cushing Disease Pathology

Corticotroph Tumors

  • Corticotroph tumors are differentiated into three subtypes based on morphology and granule distribution, with clinical implications for disease presentation and therapeutic response.

Page 10: Advanced Corticotroph Tumors

Challenges in Diagnosis

  • Smaller densely granulated tumors present specific diagnostic challenges due to their visibility on imaging.

Page 11: Gonadotropin Excess Pathology

Gonadotropic Tumors

  • Gonadotroph tumors exhibit characteristics similar to silent tumors, often requiring careful classification to distinguish from metastatic NETs.

Page 12: Nonfunctioning PitNET Classifications

Clinical Implications

  • Nonfunctioning PitNETs cover a broad range of tumors with significant implications for clinical management, diagnostic pathways, and treatment strategies.

Page 13: Identifying Synchronous PitNETs

Diagnostic Procedures

  • Increased recognition of multiple synchronous PitNETs due to improved classification protocols emphasizing transcription factor profiling.

Page 14: Risk Stratification of Tumors

Clinical Significance of Tumor Types

  • Classification of tumor types significantly impacts prognosis, treatment options, and post-operative care strategies.

Page 15: New Developments in Pituitary Blastoma

Current Findings

  • Recent classifications and findings in pituitary blastoma highlight the association with DICER1 syndrome, providing insight into pathogenesis and treatment outcomes.

Page 16: Posterior Lobe Tumor Rationale

Consolidation of Tumors

  • Historical confusion in tumor classification of the posterior lobe has led to the proposed consolidation into a unified category based on their origin.

Page 17: Neuronal Tumor Significance

Emerging Insights

  • The introduction of neuronal tumors into discussions of pituitary tumors marks a significant area of research in neuroendocrine pathology.

Page 18: Pathologist's Role and Genetic Testing

Importance of Early Recognition

  • Identifying germline predispositions for pituitary tumors is vital for patient survival and therapeutic intervention strategies.

Page 19: Summary of Recent Findings

Future Directions

  • Comprehensive evaluations of pituitary tumors continue to advance our understanding, impacting diagnosis, treatment, and overall patient outcomes.

Page 20: Conclusion

Closing Remarks

  • The new WHO classification systems reflect ongoing advancements in the field, engaging pathologists and clinicians in unified strategies for improving patient care.

References

  1. Asa, S. L., & Perry, A. (2020). Tumors of the Pituitary Gland. AFIP Atlas of Tumor and Non-Tumor Pathology.

  2. Various studies referencing the evolution of understanding and classification throughout recent literature.